Protective product for wounds, which includes substance, preventing bacterial growth in wounds

FIELD: medicine.

SUBSTANCE: described is protective product for wounds, which includes substance, inhibiting bacterial growth in wounds. Invention is characterised by the fact that it is xylite. Invention also relates to xylite application in protective products for wounds and to xylite application for obtaining composition, which has effect of inhibiting bacterial growth in wounds. Invention also relates to method of producing protective xylite-containing products for wounds.

EFFECT: product for wounds considerably improves possibility of infected wounds treatment.

38 cl, 5 dwg

 

The technical FIELD of the INVENTION

The present invention relates to a protective product for wounds, which comprises a substance that inhibits the growth of bacteria in wounds. The invention also relates to a method for production of protective products for wounds. The invention also relates to the use of protective products for wounds substance that inhibits the growth of bacteria in wounds. Additionally, the invention relates to the use of substances to obtain a composition, which has the effect of preventing the growth of bacteria in wounds.

PRIOR art

Protective products for wounds exist in many different forms, such as ointments, pastes, dressings, plasters and bacteriostatic agents.

The healing process can in principle be divided into three stages. First, the wound from just cleaned, after which the regenerated tissue, then the tissue is stabilized during the final stage of maturation and becomes less brittle and more flexible.

During the stage of regeneration of capillaries, fibroblasts and epithelial grow in the wound and synthesize new tissue. The regenerated tissue is very fragile and sensitive to external influences. When the treatment of wounds during the healing process used dressings of some type. Dressing mA the materials, used during the sensitive phase of regeneration, should be designed so that they do not fall into the wound and were flexible, and their contact surface with the wound should be soft. Dressings should also be able to absorb the excess of secretions from wounds or enable secret from the wound to pass through in the absorption portion which is located above the dressing material or which is included in bandages.

Examples of dressings used on wounds at the stage of regeneration, are full of ointments, compresses, made of gauze or nylon fabric, in combination, where appropriate, with the main part of the adsorbent. While these dressings have a lower tendency to get in the wound than traditional fibrous dressings, they, however, have several disadvantages, for example they are often caught in the wound, despite the soaking, and cause tissue damage.

Patent EP 0261167 B1 describes a dressing material, which is noticeably better. This patent relates to a dressing material for wounds, which includes a hydrophobic layer that is in direct contact with the wound during use and which is permeable to liquid. This dressing material which differs the hydrophobic layer is made of soft and elastic gel, preferably in the form of silicone gel, which is applied on setupdone element stiffness, enclosing all the fourdrinier section, but leaving the through holes. Dressings of this type actually eliminates the problem of sticking in the wound.

Another problem that can affect the healing of wounds and makes it impossible is the presence or growth of bacteria in the wound. The presence of a vast number of bacteria can also cause odor, which may be a social impediment and intractable disease. The wound may also be an entry point for more serious systemic infections that require hospitalization and a relatively long recovery period and in some cases can lead to death.

Some of the types of bacteria found in wounds, it is difficult treated with antibiotics. Processing even more difficult by the fact that intense and prolonged exposure to antibiotics that patients with wound infections are often leads to resistant strains. These are resistant to many of the effects of wound bacteria, which pose a serious threat in recent years and lead to obvious clinical problems include persistent methicillin Staphylococcus aureus (MRSA), p is icy to vancocin enterococci (VRE) and fully resistant Pseudomonas aeruginosa.

Patients suffering from diabetes, are a group that is very vulnerable from the point of view of wound infections. The number of diabetes patients is constantly increasing, and this is typical of vast areas in the world. In General, the disease weakens the body's ability to defend itself from infections and changes in the tangent perception and circulation cause wounds easier arise. In addition, a higher content of glucose in the blood and tissues creates a favorable basis for most bacteria. Beta-hemolytic Streptococcus is a group of bacteria that are particularly developed due to the good access to sugar. Streptococci are genetically very well adapted with respect to reducing sugar enzymes and their habitat, therefore, is located in the mouth, where the sugar content is the highest. These bacteria are also readily give rise to infections for diabetics, which are relatively heavy. This also applies to Streptococcus group b, which are usually bacteria with relatively low virulence for adults. Chronic wounds of the feet and legs are a particular problem for diabetics, and requires a wide range of antibiotics and relatively long periods of time to avoid amputation. There is a big risk is the group requiring protection, contributing to the development of resistance and to reduce the time interval after a period of antibiotics. Therefore, for these patients there is a very great need for alternative forms of treatment.

As is evident from the above examples, problems, including the treatment of infections of wounds, not decrease, but somewhat stronger, despite new and improved protective products for wounds and treatment methods.

The INVENTION

The present invention leads and protective product for wounds, which significantly improves the possibility of treating infected wounds.

In accordance with the invention, a protective product for RAS, which is a product of the type mentioned at the beginning, and which includes a substance that inhibits the growth of bacteria in wounds, characterized in that the substance is xylitol.

In accordance with one embodiment of the invention differs in that the protective product for RAS includes the gel, which is injected xylitol. In accordance with a modified embodiment of the invention differs in this regard, the fact that the gel is a silicone gel.

In accordance with another embodiment of the invention differs in that the protective product for RAS consists of or includes a layer that directly con is actifruit with the wound during use and which is impervious to liquid wounds due to the fact, the layer consists of gel and setupdone element stiffness, while the gel is to be applied, all surrounding the wire section, but leaving the through holes in the layer formed by the gel and the element stiffness and xylitol introduced into the gel. In accordance with one embodiment of the invention differs in this regard, the fact that the layer is hydrophobic and not adhesive to purulent wounds. In accordance with one embodiment the gel is a silicone gel.

In accordance with another embodiment of the invention differs in that the protective product for RAS includes dressings and the fact that xylitol is applied on the substrate, which is incorporated into the dressings. In accordance with one embodiment of this substrate is gauze. In accordance with another embodiment the substrate is a nonwoven fabric.

In accordance with another embodiment the substrate is a polymeric foam having open pores. In accordance with another embodiment the substrate is a water-soluble polymer foam.

In accordance with another embodiment of the specified protective product for wounds presented in the form of the dressing material and characterized in that the nonwoven material contains an absorption layer for receiving emitted from the wound fluid.

In accordance with one embodiment of the method of manufacturing the STV protective products for wounds invention differs that xylitol is applied to the substrate in the form of a solution. In accordance with one embodiment of this method the substrate is then dried.

The invention also relates to the use of protective products for wounds substance that inhibits the growth of bacteria in wounds. In accordance with the invention this application is fundamentally different to the fact that this ingredient is xylitol. In accordance with one embodiment of the use of the specified substance is in powder form. In accordance with another embodiment of the use of the specified substance is included in the gel. In accordance with another embodiment of the use of the specified substance included in the liquid solution. In accordance with another embodiment of the use of the specified substance is included in the ointment. In accordance with another embodiment of the use of the specified substance is included in the paste.

The invention also relates to a dressing material for wounds in the form of a patch containing the substance, inhibiting the growth of bacteria in wounds. In this regard, the invention is characterized by the fact that this ingredient is xylitol.

In accordance with another embodiment of the invention is the use of xylitol to obtain a composition, which has the effect of inhibiting the growth of bacteria in wounds.

In accordance with one embodiment of this application is characterized by the fact that the decree is fair, the composition includes a liquid solution, which contains xylitol.

In accordance with one embodiment of the protective product for wounds is sterile in its entirety and is packaged in a sterile manner.

As is apparent from the above, the invention consists in the use of xylitol to inhibit the growth of bacteria that are present in the wounds.

Xylitol (birch sugar) is a natural carbohydrate that is found in free form and in small quantities, especially in plant parts on trees, vegetables and fruits and, in particular, is involved in the transition metabolism of the person. Xylitol is known in organic chemistry, at least to the 1890s. German and French researchers were the first who received xylitol chemical method is more than 100 years ago. Finally xylitol has been characterized and purified during the 1930-ies. Except that xylitol has a relatively long history from a chemical point of view, it has been considered for long time as one of the few sweet carbohydrates. However, the lack of sugar during the second world war in several countries have increased the interest in xylitol. It was up until the researchers have not studied the nature of independence to insulin, so that its biological properties have become clear, and until the 1970s, xylitol has been used in several countries as podlas the living substance for diabetics due to parenteral nutrition, i.e. power given directly through the blood vessels or in connection with treatment of an insulin coma. The use of xylitol in connection with dentistry began only during the 1970's, and the first containing xylitol chewing gum to combat caries released in Finland in 1975

Xylitol is a sugar pentabasic alcohol (CH2HE(SEN)3CH2IT), which has five carbon atoms and five hydroxyl groups. Therefore, it can be described as pentitol. Xylitol belongs to polymeric alcohols (polyols), which are not sugars in the literal sense. However, biochemically they relate to sugars due to the fact that they made their sugars and can be transformed. In addition, some chemical reference works define sugar as a sweet crystalline carbohydrate that is a category that covers xylitol.

No mutagenic properties, i.e. an increase in the frequency of natural mutations that are not detected when this sugar alcohol used in the bacteriological tests (Batzinger et al.; Saccharin and other sweeteners: mutagenic properties. Science 1977; 198:944-946). In addition, a number of national and international leading experts estimated its toxicity is so low that no limit values for the allowable daily intake (Mäkinen; Dietary prevention of dental caries by xylitol - cliical effectiveness and safety; J. Appl. Nutr. 1992; 44:16-28).

Bacterial effect, which was first and primarily studied and documented, is a dental effect, which is largely the effect of the structure of this compound. Most diet polyols are hexitol. From the point of view of evolution is not, therefore, an advantage for bacteria to destroy anything other than hexitol. For this reason, most bacteria do not have the enzymatic apparatus for use pentelow for their growth.

So adding xylitol (1-10%) to the culture medium reduces the growth of bacteria that are most often found in connection with wound infections, i.e. of S. aureus (including MRSA), Streptococcus group a, b, C, and G, enterococci (including VRE) and Pseudomonas aeruginosa, with a ratio of up to about 1000, as shown by the experiments of the authors, which are described in more detail below. These results do not depend on the resistance of bacteria to antibiotics.

The growth of alpha-streptococci in the oral region is constrained by the fact that xylitol is removed in the form of a system phosphotransferase and fructose. Sugar alcohol accumulates in bacteria without the ability to break down and can be directly toxic (Trahan et al. Transport and phosphorylation of xylitol by a fructose phosphotransferase system in Streptococcus mutans. Caries Res. 1985; 19:53-63); however, if the accumulated fructose, the situation of norms which occurs, i.e. there is a relative competitiveness (Tapiainen et al. Effect of xylitol on growth of Streptococcus pneumoniae in the presence of fructose and sorbitol). This competitiveness is not equally obvious to the most common wound bacteria. Therefore, xylitol can be a barrier with different functions in these microorganisms.

In addition to the impact on growth of consumption of xylitol also affects protein synthesis in the alpha Streptococcus (Hrimech et al. Xylitol disturbs protein synthesis, including the expression of HSP-70 and HSP-60, in Streptococcus mutans. Oral Environ. Immunol. 2000; 15:249-257). In addition to other effects mutated getting loaded proteins that are required for the ability of bacteria to adapt to the adverse environment. This increases the vulnerability of bacteria.

Reducing the get of glycocalyx, sugar substance that increases the adhesive ability of bacteria to tissues wounds and colonize it, as demonstrated by S.aureus (Akiyama et al. Actions of farnesol and xylitol against Staphylococcus aureus. Chemotherapy 2002; 48:122-128). The fact that xylitol reduces the adhesion of bacteria, also demonstrated in the case of putting bacteria that cause diarrhea, and bacteria that give rise to ear inflammations and in the case of yeast fungus (Naaber et al. Inhibition of adhesion of Clostridium difficile to Caco-2-cells. FEMS Immunol. Med. Environ. 1966; 14:205-209. Kontiokari et al. Antiadhesive effects of xylitol on otopathogenic bacteria. J. Antimicrob. Chemother. 1998; 4:563-565. Pizzo et al. Effect of dietary carbohydrates on the in vitro epithelial adhesion of Candida albicans, Candida tropicalis, and Candida krusei. New Environ. 2000; 31:63-71).

Adhesion and colonization represent the first phase of the bacteria in the infection process and, therefore, are of great importance for the frequency of infection. Clinical study in which xylitol reduces the number of ear inflammation in children up to 40%, shows how important it can be (Uhari et al. Xylitol in preventing acute otitis media. Vaccine 2000; 19 Suppl. Pp 144-147).

While putting bacteria found first and foremost in connection with chronic, but not acute wound infections, their importance in wound infections is not clear. Some putting bacteria can destroy xylitol, while others need to change to get this property. Mutations often occur with a specific victim. Or bacteria can only destroy xylitol within a relatively short period of time, or bacteria grow less well in their normal environment, when you delete a sugar alcohol (Scangos et al. Acquisition of ability to utilize xylitol: disadvantages of a constitutive catabolic pathway in Escherichia coli. J. Bacteriol. 1978; 134:501-505. Inderlied et al. Growth of Klebsiella aerogenes on xylitol: implications for bacterial enzyme evolution. J. Mol. Evol. 1977; 9:181-190).

However, in the case of oral bacteria, there is a risk to choose resistant xylitol strains (Hrimech et al. 2000), when xylitol is used within dlitelnogo the period. However, this type of bacteria is rarely included in wound infections in the legs or feet.

Xylitol is only absorbed in a very mild atitelnye cells on the skin and if not absorbed, it extracts the liquid due to its hyperosmolar nature. This does not affect the activity of endogenous substances, such as defensin, which have antibacterial properties (Zabner et al. The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc. Natl. acad. Sci. USA 2002; 97:11614-11619).

High indeterminate heating xylitol solution provides it with cooling perception when in contact with mucous membranes or skin. Xylitol can also form complexes with calcium and other polyvalent cations. It is possible that these complexes contribute to the increased absorption of calcium and can contribute to remineralization in the areas of bone necrosis, a complication which is not unusual due to the deep wounds of the legs and feet. Like other sugar alcohols xylitol has the effect of stabilizing the protein in the protection of proteins in aqueous solution from denaturation, structural changes and other damage, which, sometimes, may be important in connection with the healing of wounds.

As evident from above, from the 1970-ies written a large number of works on biological t the I-V characteristics of xylitol with the main emphasis, attributable to dental context.

Despite all the research and all of that is documented in relation to the xylitol for several decades, none to the present invention does not explain or understand the fact that xylitol has a great potential in the context of wounds and can be a powerful tool to combat the presence and growth of varieties of bacteria that are the most frequent and dangerous due to infections of wounds, and that for this purpose it is possible to obtain suitable protective products for wounds. In contrast to the use of antiseptics and toxic metal ions, this occurs without any risk for the development of bacteria that are resistant to many antibiotics, or have any detrimental effect on the fabric. Also there is no risk of environmental violations or allergic reactions, as in the case of systematic use and local use, respectively antibiotics.

Xylitol can be successfully applied in many situations due to infections of wounds, where previously known protective products for wounds and methods of treatment had no effect or produced an adverse effect. As will be apparent from the following description, our experiments showed that xylitol is effective in controlling the growth of MRSA, VRE and Pseudomonas aeruginosa bacteria that cause intractable infection, vklyuchayuschimisya the costs of medical treatment and long periods of isolation. In addition, our experiments show that xylitol is effective against beta-hemolytic Streptococcus, including group b Streptococcus, which previously was a frequent reason for the relatively severe and invasive infections due to diabetic wounds.

As mentioned above, the biological effects of xylitol also naturally well-documented without showing any possible negative effects.

DESCRIPTION of FIGURES

The piece that follows, the invention will be explained with reference to the performed tests, which are shown in the accompanying drawings:

Figure 1 illustrates in diagrammatic form the growth ofS. Aureusin the medium without the addition of xylitol and, respectively, with the addition of it with different content.

Figure 2 illustrates in diagrammatic form the growth ofS. Aureus(very stable) in a nutrient medium without the addition of xylitol and, respectively, with the addition of it with different content.

Figure 3 illustrates in diagrammatic form the growth of group b Streptococcus in a nutrient medium without the addition of xylitol and, respectively, with the addition of it with different content.

Figure 4 illustrates in diagrammatic form the growth of Streptococcus group G in a nutrient medium without the addition of xylitol and, respectively, with the addition of it with different content.

Figure 5 illustrates in section aramnau the form of the growth of P. Aeruginosain the medium without the addition of xylitol and, respectively, with the addition of it with different content.

INCARNATION

As evident from the accompanying drawings, executed tests show extremely good effect on inhibiting the growth of common bacterial species found in the wounds.

The experiments were carried out as follows.

The bacterial strains were stored at -70°C. Immediately before each experiment these strains were pulled out and put on a Cup of blood and kept overnight at 35°C. In all experiments used the same incubator. After this loop colonies which grew were kept in heart-brain broth (BHI) for 18 hours. 100 μl of this broth was inoculated into 3-5 ml of fresh BHI broth with the addition of xylitol or without him. Added to different content of xylitol. As evident from figure 1-5, the content of xylitol were 1%, 2,5%, 5% and 10%.

The transmittance or transparency was measured from 0 hours and then every hour for 6 hours on the Biolog turbidimeter from Biolog Inc., Hayward, CA, USA. The growth of bacteria reduces transparency, i.e. the lower the transmittance, the higher the growth of bacteria.

At the beginning and after 6 hours 100 μl of broth was cultured and counted the number of live bacteria. Then compare the value of the coefficient of the prop is for sale and the number of bacteria (colony-forming units/ml) in test tubes with xylitol and without it.

On the graph shown in figure 1, you can see that the translucency of bacteriaS. Aureusi.e. called hospital bacteria in BHI without adding xylitol gradually decreased from 100 at time point 0 to 20 at time point 6 hours, indicating that the bacteria were growing very strongly.

On the same graph you can see that the translucency is still more than 60%, after 6 hours in a nutrient solution to which was added 10% xylitol, which shows that the growth of bacteria greatly weakened compared to the solution without xylitol. Moreover, as is evident from the curve for BHI containing 10% added xylitol, hardly any bacterial growth is quite 2 hours.

The graph in figure 2 shows the curves where the optionStaphylococcus aureuswas used with the addition of xylitol or without him. The bacterium is shown in figure 2, is a strain of MRSA, showing a very high degree of resistance, and where only one or two types of antibiotic are possible alternatives of treatment. The medicines are more than 1000 SEK for a day, compared with the usual price of about 55-70 SEK per day. In addition, superstability leads to the fact that patients are infected with MRSA should be taken care of in separate rooms with special hygienic regulations and not be allowed to move themselves in the hospital. This, of course, very expensive and painful for patients.

As evident from figure 2, the addition of xylitol to the nutrient solution containing the bacteria that causes bacterial growth in solution inhibited very effectively. Growth is constrained in increasing degree as increasing the number of added xylitol. After 6 hours the translucency in the presence of 10% added xylitol is more than 70%, while the translucency for a solution without any addition of xylitol is only about 30%. Figure 2 was not measured values after 2 hours.

Figure 3 shows the graph corresponding to the graphs shown in figures 1 and 2, but in this case, Streptococcus group C. This type of bacteria commonly found in severe diabetic wounds, particularly wounds on the legs and feet, which cause the risk of life-threatening infections and necrosis of bones.

As can be seen in figure 3, the data growth of bacteria can effectively inhibit the addition of xylitol.

Accordingly, as in figure 1-3, 4 and 5 show two additional bacteria, i.e. Streptococcus group G andP. aeruginosathat found in wounds. As shown by these graphs, xylitol is also very effective for inhibiting the growth data of bacterial strains.

In accordance with the invention the safety of the product for wounds, includes xylitol, can be manufactured in various ways.

One way is to add the xylitol in powder form to silicone gel. This gel is chemically crosslinked silicone gel (polydimethylsiloxane gel), for example, two-component, addition vulkanizmi at room temperature with a platinum catalyst silicone (RTV). Examples of gels that can be used are SiGel from Wacker-Chemie GmbH, Burghausen, Germany and MED-6430 from NuSil Technology, Carpinteria, USA. Examples of self-adhesive gels are also described in GB-A-2192142, GB-A-2226780 and EP-A1-0300620. There might also be other hydrophobic gels, such as hydrophobic polyurethane gels.

In accordance with one embodiment of xylitol in powder form can be added to the liquid silicone aforementioned types and mix with it. Then this mixture adhesive vulcanized for cross-linking of polymer mesh at a temperature of 90-130°C. Silicone gel containing xylitol can be used as a protective product for wounds, especially in combination with external dressing material for wounds.

Xylitol is commercially available in powder form, approximately the same particle size as granulated sugar. In accordance with one embodiment of powdered xylitol can be crushed to obtain a powder with a smaller particle, the possession is forming a higher specific surface. Mixing with silicone leads to an increase of the existing surface and this will increase the excretion of xylitol from silicone gel containing xylitol, compared with the same silicone gel and xylitol, with larger particle size. The size of the particles of xylitol can thus be used to modify the rate of release of silicone gel that contains xylitol.

Alternative xylitol can first be dissolved in water; after which they receive a suspension of silicone and solution of xylitol and subsequent vulcanization of the suspension.

Silicone gel containing xylitol in the form of particles or added to the solution, can be used to produce a protective product for wounds, which includes a layer which is in contact with the wound during use, which is permeable to liquid wound and which includes a specified silicone gel containing xylitol and satapathy element stiffness. The gel is applied so that it covers all parts of the grid, but left through holes in the layer formed by the gel and the element stiffness. The dressing material which is a material of this type, but which does not contain xylitol, is described in the patent authors EP V, the full content of which is incorporated by reference into this description.

The invention is not limited to described what use embodiments and several modifications within the scope of the subsequent claims claims.

For example, dressings may contain xylitol in solution or in the form of particles, which is applied or injected into a substrate, such as a polymeric foam having open pores. An example is a polyurethane foam type Hypol®from Hampshire Chemical Corporation, Lexington, Massachusetts, USA.

Other examples of substrates are gauze, hot-melt adhesive and non-woven fabrics.

Protective product for wounds completely sterilized and packaged sterile.

1. Protective product for wounds, comprising a substance that inhibits the growth of bacteria in wounds, characterized in that the substance is xylitol.

2. Protective product for wounds according to claim 1, characterized in that the protective product for RAS includes ointment, which contains xylitol.

3. Protective product for wounds according to claim 1, characterized in that the protective product for RAS includes powder, which contains xylitol.

4. Protective product for wounds according to claim 1, characterized in that the protective product for RAS includes the gel, which introduced xylitol.

5. Protective product for wounds according to claim 4, characterized in that the gel is a silicone gel.

6. Protective product for wounds according to any one of claims 4 and 5, characterized in that xylitol is introduced into the gel in crystalline form.

7. Protective product for wounds according to claim 1, characterized in that the decrees of the data protection product for RAS contains a polymer foam, in which xylitol is introduced in an aqueous solution, in connection with which the formed polymer foam.

8. Protective product for wounds according to claim 1, characterized in that the protective product for RAS contains a polymer foam, in which xylitol is entered in crystalline form, in connection with which the formed polymer foam.

9. Protective product for wounds according to claim 7 or 8, characterized in that the polymeric foam contains water-soluble polymer.

10. Protective product for wounds according to claim 1, characterized in that the protective product for RAS layer consists of or includes a layer which is in direct contact with the wound during use and which is permeable to liquid wounds, and the layer includes a gel and satapathy element stiffness, and the gel is to be applied so that it covers all parts of the grid, but leaves the through hole on the layer formed by the gel and the element stiffness and xylitol entered into a gel.

11. Protective product for wounds according to claim 10, characterized in that the specified satapathy element stiffness is elastic, and the gel is soft and supple.

12. Protective product for wounds according to claim 10, characterized in that the layer is hydrophobic and does not stick to the festering wounds.

13. Protective product for wounds according to claim 10, characterized in that the gel is silicone the m gel.

14. Protective product for wounds on one of PP-13, characterized in that the element stiffness includes a soft, flexible and elastically stretchable mesh textile material.

15. Protective product for wounds according to claim 1, characterized in that the protective product for RAS includes dressings and the fact that xylitol deposited on a substrate, which is included in this dressings.

16. Protective product for wounds according to item 15, wherein the substrate is a gauze.

17. Protective product for wounds according to item 15, wherein the substrate is a nonwoven fabric.

18. Protective product for wounds according to item 15, wherein the substrate is a polymeric foam having open pores.

19. Protective product for wounds according to item 15, wherein the substrate is a water-soluble polymer foam.

20. Protective product for wounds according to any one of claims 1 to 5 in the form of a dressing material, characterized in that the nonwoven material contains absorbent layer for receiving emitted from the wound fluid.

21. Protective product for wounds according to any one of claims 1 to 5, characterized in that the protective product for wounds is sterile as a whole and is packaged in a sterile manner.

22. Method for the production of protective products for wounds on any of PP-19, characterized in that xylitol is applied to the substrate in the form of a solution.

23. The method according to item 22, wherein the substrate is then dried.

24. The method according to item 22, wherein the protective product for wounds and applied the packaging is sterilized.

25. The use of a substance in the protective products for wounds, which inhibits the growth of bacteria in wounds, characterized in that the substance is xylitol.

26. Use A.25, characterized in that the substance is in powder form.

27. Use A.25, characterized in that the substance is included in the gel.

28. Use A.25, characterized in that the specified substance included in the liquid solution.

29. Use A.25, characterized in that the substance is included in the ointment.

30. Use A.25, characterized in that the substance is included in the paste.

31. The use according to any one of p-30, characterized in that the protective product for wounds is sterile as a whole and Packed in a sterile manner.

32. Dressings for wounds in the form of a patch containing a substance for inhibiting the growth of bacteria in wounds, characterized in that the substance is xylitol.

33. Dressings for wounds on p, characterized in that the dressing material for wounds is completely sterile and Packed in a sterile manner.

34. The use of xylitol to obtain a composition, which is blade effect of inhibiting the growth of bacteria in wounds.

35. The application 34, characterized in that the said composition comprises a liquid solution that contains xylitol.

36. The application 34, characterized in that the composition comprises a gel, which introduced the xylitol.

37. Use p, characterized in that said gel comprises a hydrophobic gel, preferably a silicone gel.

38. The use according to any one of p-37, characterized in that the said composition is sterile and Packed in a sterile manner.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used in experimental and clinical surgery, traumatology for application of film-forming compositions on wound surface. Described is medicinal composition based on medicinal preparation and BF-6 glue where as medicinal components are used xymedone, ximedone hydrochloride, dimexide, dioxydin, lidocaine hydrochloride or xymedone, brilliant green, lidocaine hydrochloride or xymedone, methylene blue, lidocaine hydrochloride or ximedone hydrochloride, potassium permanganate, lidocaine hydrochloride.

EFFECT: glue bandage prevents from external influence, contamination, stimulates formation of strong soldered layer and epithelisation.

5 cl, 1 tbl, 12 dwg , 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmacology, namely to pharmaceutical composition applied for external and local treatment of pyodestructive processes in skin and mucous membranes and characterised by that it contains Tilorone and at least one end additive chosen from: agent with antibacterial activity to gram-positive and/or gram-negative bacteria, antimicotic, local anaesthetic agent, reparative stimulator, hypooxidant, biogenic elements, a base or their mixture in certain ratio.

EFFECT: invention ensures extended application of the known active agent Tilorone, restored local immunity and biocoenosis of skin and mucous membranes in treatment of pyodestructive processes, anaesthetic effect; additional reparative stimulation; improved microcirculation in lesion focus, reduced inflammatory reactions in skin and mucous membranes, decreased secondary tissue neurosis of the affected areas, improved microcirculation in lesion focus, reduced itching, maintained high therapeutic activity and usability, more rapid and improved healing.

10 cl, 19 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine and pharmacology, namely, pharmaceutical composition applied at treatment of purulent-destructive processes of a skin and mucosas at external and local application, characterised that it contains tylorone, an emulsion of perfluoroorganic bonds, and as, at necessity, a hydrophylic basis at a certain parity of components.

EFFECT: invention provides expansion of a scope of known active substance - tylorone, restoration of tissue immunity and biocenosis of a skin and mucosas at treatment of purulent-destructive processes of a skin, depression of a secondary necrosis of tissues on the amazed sites, microcirculation improvement in the lesion centre, cupping of inflammatory reactions, reduction of an itch maintenance of high therapeutic activity and convenience in use, acceleration and healing improvement.

19 ex, 4 cl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to remedy and method of obtaining remedy for wound treatment. Method of obtaining remedy for wound treatment lies in the following: from fly eggs larvae are gown, which can be introduced in to wound under treatment, larvae are contaminated with bacteriophages in such way that introduced larvae are bacteriophage carriers. In order to realising said method, in particular, larvae of genus Lucilia are used. Also claimed are method and remedy for wound treatment, with tampon containing bacteriophages and soaked with larva secret on wound.

EFFECT: treatment of wounds with fly larvae is improved by contamination of larvae with bacteriophages.

14 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine and pharmacology and represents pharmaceutical composition for treating purulent destructive lesions of mucous membrane and skin, characterised by containing tilorone mixed with soft formable base, where as soft formable base it contains hyperosmolar substances selected from group.

EFFECT: invention ensures recovery of local immunity and biocoenosis of skin and mucous membranes in case of purulent destructive skin processes, reduction of secondary tissue necrosis on affected sections, high therapeutic activity and convenience in use.

7 cl, 19 ex

FIELD: beiotechnology.

SUBSTANCE: invention concerns production of items with expressed bioactivity and can be applied as healing and preventive medicine in medical cosmetology, balneology, medicine and veterinary. Method involves extraction of bioactive substances from unossified antlers at 40°C or lower temperature, conservation and gelatinisation agent addition to obtain aqueous solution of conservation agents represented by methylparaben and propylparaben. Extraction of bioactive substances is performed by conservation agent extraction to the solution by ultrasonic method in cavitation mode at weight ration of unossified antlers to aqueous solution of 1:1-10 for time period sufficient to obtain required extract concentration. Carbopol is used as gelatinisation agent and mixed with distilled water preliminarily and aged till imbibition, then neutralising agent is added in amount sufficient to form gel mass, further neutralised by adding citric acid solution to 6-7.5, and aqueous solution of unossified antlers and 1-30 wt % of water retentive component are added to obtained gel mass in portions with stirring.

EFFECT: obtaining high-quality gel based on aqueous solution of unossified antlers by ultrasonic extraction of bioactive substances.

2 cl, 5 ex, 2 tbl

Wound dressing // 2349348

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly media of surfacial wound and burn treatment, and can be applied in surgery, traumatology, therapy, ophthalmology, veterinary and adjoining fields. Wound healing medium is superexpanding polymer matrix including collagenase in amount of 1-10 wt % of matrix weight. Superexpanding polymer matrix is a matrix obtained by copolymerisation of at least two monomers of group including maleic, crotonic and acrylic acids and/or their derivatives in the presence of binding agent.

EFFECT: efficient wound healing agent viable for composition standardisation.

5 cl, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method of obtaining wound bandage material is claimed. Method involves obtaining protein polymer by protein reaction with polyfunctional spacer or its activated derivative. Preferred polyfunctional spacer is polycarboxylic acid, especially dicarboxylic acid. Protein polymers obtained with such spacers can be applied in a wide range of therapeutic purposes, including wound bandage materials, therapeutic agent delivery to organism, and bioadhesive and sealing substances.

EFFECT: obtaining material taking exact shape of wound filling wound hollow completely without irritation of exposable tissues.

27 cl, 2 dwg, 13 tbl, 12 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention represents pharmaceutical composition for treatment of purulo-destructive affections of skin and mucous membranes, applied for external and local use and characterised by that it contains Tilorone and base additives chosen from group: substance of antibacterial activity in respect to gram-positive and/or gram-negative bacteria, antimicotic, local anaesthetic, reparative process stimulator, hypooxidiser, biogenic elements and base, or their mixture in certain ratio.

EFFECT: extended application of Tilorone, restored local immunity and biocoenosis of skin and mucous membranes associated with treatment of purulo-destructive skin processes, provided anaesthetic effect; additional stimulation of reparative processes; improved microcirculation in lesion focus, reduced inflammatory reactions, ensured high therapeutic activity and useability, accelerated and improved healing.

10 cl, 19 ex

FIELD: medicine; dermatology.

SUBSTANCE: in addition to Griseofulvin, Pioployphage is introduced orally in dosage 30-50 ml or on 1-2 tablets twice a day within 14 days.

EFFECT: antibacterial action, nonspecific phagocytosis stimulation, intensified immune response on infestant antigen, escaping complications associated with secondary pyogenic infection.

4 tbl, 2 ex

FIELD: sanitary and hygienic facilities.

SUBSTANCE: superabsorption product of invention comprising liquid-impermeable base layer; liquid-absorbing intermediate layer containing partially neutralized acid-behaving hydrophilic polymer, in particular surface cross-linked polyacrylate; and liquid-permeable non-absorbing top layer is distinguished by containing alkali-neutralizing additive uniformly spread in absorbing intermediate layer.

EFFECT: enhanced controlling unpleasant smell and inhibited microbial growth.

10 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with applying anti-fetor additives containing phosphorus-bearing compounds. It is described a disposable absorbing product that contains liquid-permeable covering, absorbing internal layer and anti-fetor additive at the quantity ranged 0.1-1 g/sq. inch.

EFFECT: higher efficiency of application.

15 cl, 1 ex

The invention relates to the use of absorbent particles in absorbent structures and disposable absorbent products

The invention relates to medicine, specifically described absorbent article such as a diaper, a sanitary pad, a protective device which is used in case of incontinence, dressing on a frame or the like, containing an absorbent body (12) concluded between the non-permeable for liquids rear sheet (11) and a layered material (1) in the form of permeable for liquids upper sheet (2) and permeable to liquid, providing a moving liquid sheet (3), thus providing a moving liquid sheet (3) is located closest to the absorbent body (12), moreover, in the specified product is permeable to liquid, the upper sheet (2) and ensure that the movement of the liquid sheet (3) are connected to each other, and the absorbent body includes a partially neutralized superabsorbent

The invention relates to an absorbent article that contains a synergistic combination of nutrients for pH regulation in the form of a partially neutralized overabsorbed material and lactic acid bacteria, after wetting and worn near the skin, the product has a pH in the range of 3.5 to 5.5, preferably in the range of 3.5-4.9 and most preferably in the range of 4.1 to 4.7

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used in experimental and clinical surgery, traumatology for application of film-forming compositions on wound surface. Described is medicinal composition based on medicinal preparation and BF-6 glue where as medicinal components are used xymedone, ximedone hydrochloride, dimexide, dioxydin, lidocaine hydrochloride or xymedone, brilliant green, lidocaine hydrochloride or xymedone, methylene blue, lidocaine hydrochloride or ximedone hydrochloride, potassium permanganate, lidocaine hydrochloride.

EFFECT: glue bandage prevents from external influence, contamination, stimulates formation of strong soldered layer and epithelisation.

5 cl, 1 tbl, 12 dwg , 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Described is method and single-unit subsaturated plaster with unregulated rate for introduction of fentanyl and its analogues to subject through skin.

EFFECT: anesthesia during long period of time.

5 cl, 8 dwg, 4 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: method of obtaining wound bandage material is claimed. Method involves obtaining protein polymer by protein reaction with polyfunctional spacer or its activated derivative. Preferred polyfunctional spacer is polycarboxylic acid, especially dicarboxylic acid. Protein polymers obtained with such spacers can be applied in a wide range of therapeutic purposes, including wound bandage materials, therapeutic agent delivery to organism, and bioadhesive and sealing substances.

EFFECT: obtaining material taking exact shape of wound filling wound hollow completely without irritation of exposable tissues.

27 cl, 2 dwg, 13 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine and claims plaster for local application, containing capsaicin or its analogue, method of its manufacturing, and application. Invention concerns plaster for local application, including substrate layer impermeable for therapeutic compound, self-gluing matrix based on polysiloxanes and containing capsaicin or therapeutic compound similar to capsaicin, and protection film removed before application; where matrix includes microreservoirs for fluid based on amphiphilic solvent in which therapeutic compound is placed in completely dissolved form, and concentration of therapeutic compound in microreservoir drops is lower than saturation concentration. Invention claims method of plaster production and application in neuropathological pain mitigation.

EFFECT: system stability required for high grade of active component deliberation.

15 cl, 4 tbl, 3 dwg, 5 ex

Up!